The startup develops nuclide drugs that combine positron emission tomography (PET) contrast agents with targeted radiotherapy to enhance the diagnosis and treatment of pancreatic cancer. This approach enables healthcare providers to deliver more precise and effective therapeutic interventions for patients suffering from this challenging disease.
Funding
Funding not disclosed
Founders
Product
Problem
Pancreatic cancer is difficult to diagnose and treat effectively due to its aggressive nature and late-stage detection. Current diagnostic methods often lack the precision needed for early and accurate identification, while traditional radiotherapy can damage healthy tissue surrounding the tumor. This results in limited treatment options and poor outcomes for patients.
Solution
The startup is developing a novel class of nuclide drugs that integrate positron emission tomography (PET) imaging agents with targeted radiotherapy. This dual-modality approach aims to improve both the diagnosis and treatment of pancreatic cancer. The PET component allows for enhanced visualization and precise localization of tumors, while the targeted radiotherapy delivers radiation directly to cancer cells, minimizing damage to surrounding healthy tissue. By combining these functionalities, the technology seeks to enable more accurate diagnoses, personalized treatment plans, and improved therapeutic outcomes for patients with pancreatic cancer.
Target Audience
The primary target audience includes oncologists, radiologists, and nuclear medicine physicians specializing in pancreatic cancer treatment, as well as hospitals and cancer centers.
Features
- PET imaging agents for high-resolution tumor visualization and staging
- Targeted radiotherapy delivery to maximize cancer cell destruction while sparing healthy tissue
- Theranostic approach combining diagnostic and therapeutic capabilities in a single agent
- Potential for personalized treatment plans based on individual patient tumor characteristics